Differential expression of sirtuins in the aging rat brain

Nady Braidy, Anne Poljak, Ross Grant, Tharusha Jayasena, Hussein Mansour, Tailoi Chan-Ling, George Smythe, Perminder Sachdev and Gilles J. Guillemin

Although there are seven mammalian sirtuins (SIRT1-7), little is known about their expression in the aging brain. To characterize the change(s) in mRNA and protein expression of SIRT1-7 and their associated proteins in the brain of “physiologically” aged Wistar rats. We tested mRNA and protein expression levels of rat SIRT1-7, and the levels of associated proteins in the brain using RT-PCR and western blotting. Our data shows that SIRT1 expression increases with age, concurrently with increased acetylated p53 levels in all brain regions investigated. SIRT2 and FOXO3a protein levels increased only in the occipital lobe. SIRT3-5 expression declined significantly in the hippocampus and frontal lobe, associated with increases in superoxide and fatty acid oxidation levels, and acetylated CPS-1 protein expression, and a reduction in MnSOD level. While SIRT6 expression declines significantly with age acetylated H3K9 protein expression is increased throughout the brain. SIRT7 and Pol I protein expression increased in the frontal lobe. This study identifies previously unknown roles for sirtuins in regulating cellular homeostasis and healthy aging.

Keywords: aging, sirtuins, p53, brain, longevity

Introduction

Sirtuins or “silent information regulators” of gene transcription, are a family of enzymes which are expressed throughout all phyla of life. Accumulating evidence suggests that this unique class of histone deacetylases are key regulators of numerous physiological processes, particularly in aging in multiple organisms (Porcu and Chiarugi, 2005; Berdichevsky and Guarente, 2006; Longo and Kennedy, 2006; Smith and Denu, 2006; Pallas et al., 2008; Schwer and Verdin, 2008). Gene silencing by this family of enzymes has been correlated directly with longer lifespan in yeast and worms (Yang and Sauve, 2005). In yeast, Sir2 plays a critical role in transcriptional silencing and in genomic stability (Lamming et al., 2004; Denu, 2005). The key question is whether sirtuins regulate healthier aging in mammals.

Seven Sir2 homologs (SIRT1-7) have been identified in mammals (Porcu and Chiarugi, 2005; Pallas et al., 2008). Mammalian sirtuins have diverse locations and multiple targets, and affect a broad range of cellular processes (Supplementary Figure 1). SIRT1 is the human homolog of sir2 and appears to be involved in several physiological functions including the control of gene
expression, cell cycle regulation, apoptosis, DNA repair, metabolism, and aging (Anastasiou and Krek, 2006; Qin et al., 2006; Smith and Denu, 2006). SIRT1 is localized in the nucleus and can deacetylate numerous proteins such as tumor suppressor protein (p53), Ku70, NF-κB, and forhead proteins which modulate genes that control cellular stress resistance (Smith, 2002). The deacetylation activity of specific sirtuins is dependent on the intracellular NAD+ content (Sauve et al., 2006). They catalyze a unique reaction that releases nicotinamide, acetyl ADP-ribose (AADPR), and the deacetylated substrate (Sauve et al., 2006). It has been shown that increased SIRT1 activity in human cells can delay apoptosis and rescue vulnerable cells with additional time to repair after repeated exposure to oxidative stress (Howitz et al., 2003).

Mammalian SIRT2 is predominantly a cytoplasmic protein (North et al., 2003). It can deacetylate several cytoskeletal proteins, including α-tubulin, histones, and forhead proteins, although the physiological effect of deacetylation of these proteins by SIRT2 remains unknown (Choudhuri et al., 2003; North et al., 2003; Brunet et al., 2004; van der Horst et al., 2004). SIRT2 protein expression levels also appear to increase during the mitotic phase of the cell cycle, and overexpression can delay mitosis (Dryden et al., 2003). Consistent with the idea that SIRT2 can protect against neurodegenerative pathology in mouse models of Alzheimer’s disease, overactivation of SIRT2 has been shown to protect against axonopathy and neurodegeneration in a mouse model of Wallerian degeneration (Arraki et al., 2004; Tang and Chua, 2008). Small-molecule inhibitors targeting SIRT2 have been shown to attenuate several models of neurodegeneration in vivo (Choudhuri et al., 2003; North et al., 2003; Brunet et al., 2004; van der Horst et al., 2004). Therefore, it is of significant interest to determine the anatomical and functional changes of SIRT2 in the brain during aging.

Mitochondria represent the primary site for the production of reactive oxygen species (ROS) through one-electron carriers in the respiratory chain (Beal, 1995). This dynamic organelle is highly vulnerable to the cytotoxic effect of oxidative stress, as evidenced by extensive lipid peroxidation, protein oxidation and mitochondrial DNA (mtDNA) mutations (Beal, 1995, 2007; Mawrin et al., 2003; Andersen, 2004). Experimental evidence of respiratory chain defects (Braidy et al., 2011) are in accordance with the mitochondrial theory of aging. The role of the mitochondrial SIRT3-5 is of great interest with regard to mammalian aging and age-related brain disorders. Do mammalian sirtuins regulate metabolism and the oxidative stress response in the brain during aging? Recently, Ozden et al. (2011) showed that SIRT3 responds to changes in mitochondrial redox status by altering the enzymatic activity of specific downstream targets, including manganese superoxide dismutase (MnSOD). MnSOD is the primary mitochondrial ROS scavenging enzyme which modulates ROS levels as well as metabolic homeostatic poise (Ozden et al., 2011). However, no study to our knowledge has examined SIRT3-5 mRNA and protein expression levels over a mammalian aging time course.

SIRT6, is another nuclear specific protein, is a histone H3-lysine 9 (H3K9) deacetylase, that is necessary to promote longevity (Liszt et al., 2005; Mostoslavsky et al., 2006; Koltai et al., 2010). SIRT6 knockout mice display premature aging symptoms, including excessive loss of subcutaneous fat and a significant reduction in bone density, and die within 4 weeks of birth (Mostoslavsky et al., 2006). These animals also demonstrate impaired DNA base excision repair (BER) and several metabolic phenotypes (Mostoslavsky et al., 2006). However, the mechanism by which SIRT6 regulates BER remains unknown. It is interesting to know whether metabolic changes during aging are associated with SIRT6.

The least characterized of the sirtuins, SIRT7, is localized in the nucleolus of mammalian cells. Ford et al. (2006) showed that SIRT7 protein expression levels correlated with tissue proliferation and its expression is reduced in non-proliferating tissue, such as the heart, brain and muscle (Ford et al., 2006). Recently, SIRT7 has been associated with cellular growth and metabolism (Ford et al., 2006). In particular, SIRT7 has been associated with rDNA transcription, and SIRT1, an inducer of p53, share similar features that exhibit a pro-survival role in cells.

Owing to the importance of mammalian sirtuins in physiology and aging, we hypothesized that they may be differentially expressed in the rat brain and may regulate various targets involved in metabolic processes and neurodegenerative diseases. To date, very little is known about the anatomical distribution of these sirtuins throughout the brain or changes which may occur during aging. Using real-time RT-PCR and western blot analysis, we have quantified changes in SIRT1-7 mRNA and protein expression levels in the brains of female wistar rats aged from 3 to 24 months, spanning life stages from young adulthood to old age (Coleman, 1989). We also sought to examine the functional role of sirtuin expression/activity by assaying superoxide and fatty acid oxidation levels as well as known targets of sirtuin deacetylation activity, including p53, FOXO3a, MnSOD, CPS-1, histone H3K9, and polymerase-I. The implications of these findings for the aging process are discussed within the context of key sirtuin-related metabolic processes.

Materials and Methods

Animals

Female wistar rats were used in the following age groups: 3 months (equivalent to a young human adult aged 20 years), 12 months (equivalent to a middle-aged human aged 40 years) and 24 months (equivalent to an aged human greater than 80 years) (Collier and Coleman, 1991). The animals were individually housed in an environmentally controlled room under a 12 h alternating light/dark cycle at 23°C and were fed commercial rat chow and water ad libitum. All experiments were performed with the approval of the Animal Ethics Committee of the University of Sydney. Anesthesia was induced with a mixture of O2, NO2, and 5% halothane, followed by an intraperitoneal injection of sodium pentobarbitone (60 mg/kg), and perfused transectally as previously described (Chan-Ling, 1997; Mansour et al., 2008). Whole brain was removed, washed with phosphate buffered saline, and mitochondrial fraction prepared as reported earlier (Ozden et al., 2011).
saline solution (Invitrogen) and used immediately for a variety of biochemical and histochemical procedures.

**RT-PCR for SIRT1-7 mRNA Expression**

For the gene expression studies, RNA was extracted from the frontal, temporal, and occipital lobes and hippocampus, using Qiagen RNaseasy mini kits (Hilden, Germany). Quantitative and qualitative analysis of RNA samples was performed using a 2100 Bioanalyzer (Agilent Technologies) to ensure they were of sufficient quality to generate reliable data (RIN 10). The cDNA was prepared using the SuperScript III First-Strand Synthesis System and random hexamers (Life Technologies, Carlsbad, CA). Gene expression was determined using real-time PCR as described previously (Lee et al., 2010). Briefly, for each reaction, 2 µL of diluted cDNA, 10 µL of SYBR green master mix, 0.15 µL of 10 µM forward and reverse primers and 7.7 µL of nuclease-free water was used, making a total volume of 20 µL. Q-PCR was carried out using the Stratagene Mx3500P Real-Time PCR system (Sydney, Australia). The relative expression levels of SIRT1-7 were calculated using a mathematical model based on the individual Q-PCR primer efficiencies and the quantified values were normalized against the housekeeping gene Glyceraldehyde Phosphate Dehydrogenase (GAPDH) (Lee et al., 2010). The primer sequences are shown in Supplementary Table 1.

**Western Blots for Assaying Protein Expression of SIRT1-7, Total/Acetylated p53, MnSOD and FOXO3**

The frontal, temporal, occipital lobes and hippocampus were carefully dissected from the whole brain and homogenized in RIPA lysis buffer containing 50 mM Tris-HCl (pH 7.4); Igepal 1% (w/v); 0.25% (w/v) Na-deoxycholate; 1 mM EDTA; 150 mM NaCl; 1 µg/ml each of protease inhibitors aprotinin, leupeptin and pepstatin; 1 mM Na3VO4; and 1 mM NaF. After 1 h, the homogenate was centrifuged (14,000 g, 10 min). The nuclear extract was immediately stored allowed to incubate on ice (30 min) followed by centrifugation (10,000 g, 10 min). The nuclear extract was immediately stored at −80°C for later application of SIRT1 deacetylase activity assay.

**SIRT1 Deacetylase Activity**

SIRT1 deacetylase activity was evaluated in nuclear extracts from the frontal, temporal, occipital lobes and hippocampus of young, middle-aged, and aged rats, using the Cyclex SIRT1/Sir2 Deacetylase Fluorometric Assay Kit (Nagano, Japan). The final reaction mixture (100 µL) contained 50 mM Tris-HCl (pH 8.8), 4 mM MgCl2, 0.5 mM DTT, 0.25 µM Lysyl endopeptidase, 1 µM Trichostatin A, 200 µM NAD+, and 5 µL of nuclear sample. The samples were mixed well and incubated for 10 min at room temperature and the fluorescence intensity (ex. 340 nm, em. 460 nm) was measured at 30 s intervals for a total of 60 min immediately after the addition of fluorosubstrate peptide (20 µM final concentration) using Fluostar Optima Fluorometer (NY, NY) and normalized to the total protein content. The results are reported as relative fluorescence/µg of total protein (AU).

**Measurement of Superoxide**

Assay of superoxide was performed using the lucigenin-enhanced chemiluminescence assay as previously described (Brown et al., 2006). Briefly, brain homogenates from the frontal, temporal, occipital lobes and hippocampus were placed in a polypropylene tube containing 0.5 mL PBS and lucigenin (5 µmol/L). The tube was placed in a Promega GloMax luminometer (Madison, WI) to detect the relative light units emitted. Background counts were determined from tissue-free preparations, and the luminescence subtracted from the brain sample readings.

**Manganese Superoxide Dismutase (MnSOD) Activity**

MnSOD activity was measured as previously described (Spitz and Oberley, 1989). The enzymatic activity of MnSOD was determined based on the competition between MnSOD and an indicator molecule for the generation of superoxide from xanthine and xanthine oxidase, in the presence of 5 mM NaCN, an inhibitor of CuZnSOD activity.

**Fatty Acid Oxidation**

Fatty acid oxidation was measured as previously described (Nasrin et al., 2010). Briefly, brain homogenates from the frontal,
temporal, occipital lobes and hippocampus were incubated in serum-free media containing 0.5 mg/ml bovine serum albumin and \(^{3}H\) palmitate (10 \(\mu M\) cold palmitate and 8.93 \(\mu Ci/ml\) \(^{3}H\) palmitate) for 90 min. Afterwards, 100 \(\mu l\) of homogenate mixture was transferred to a 9-well filter plate containing 100 \(\mu l\) of phosphate-buffered activated charcoal slurry. The plate was centrifuged (2800 g, 45 min, 25°C), the charcoal-containing plate was discarded and the filtrate was counted using a Beckman LS6500 scintillation counter (Beckman-Coulter, Brea, CA).

Bradford Protein Assay for the Quantification of Total Protein
SIRT1 activity, superoxide levels, MnSOD activity, and fatty acid oxidation were adjusted for variations in total protein concentration using the Bradford protein assay (Bradford, 1976).

Data Analysis
Results obtained are presented as the means ± the standard error of measurement (Koch et al., 2006) of at least eight animals per age group analyzed in duplicate. One-Way analysis of variance (ANOVA) and post-hoc Tukey’s multiple comparison tests were used to determine statistical significance between treatment groups. Differences between treatment groups were considered significant if \(p < 0.05\).

Results
Regional Changes in Sirtuin mRNA and Protein Expression in the Aging Rat Brain
We performed RT-PCR and Western blotting analysis to examine changes in sirtuin mRNA expression in various regions of the brain from young, middle-age and aged animals. We observed a significant increase in SIRT1 mRNA expression in the frontal, temporal, occipital lobes and hippocampus with age (Table 1, Supplementary Figure 2), consistent with an increase in SIRT1 protein expression in these regions (Table 2). Interestingly, SIRT2 mRNA (Table 1, Supplementary Figure 1) and protein expression (Table 2) levels increased only in the occipital lobe, with no significant increase observed in the other brain regions. SIRT3 mRNA and protein expression declined significantly in the hippocampus and frontal lobe (Tables 1, 2, Supplementary Figure 2). In contrast to the increase in SIRT1 expression, our data also shows that SIRT6 mRNA levels declined significantly with age, consistent with reduced SIRT6 protein expression in the same brain regions (Tables 1, 2, Supplementary Figure 2). As well, SIRT7 mRNA (Table 1, Supplementary Figure 2) and protein (Table 2) expression was increased only in the frontal lobe with aging.

SIRT1 Deacetylation Activity but Not Protein Expression Declines with Aging
SIRT1, an NAD\(^{+}\) dependent deacetylase is primarily localized in the nucleus (Sauve et al., 2006). Therefore, we assessed the activity of SIRT1 in nuclear extracts from selected regions of the brain in aging rats. By 12 months a significant decline in SIRT1 activity in all brain regions was observed with the greatest decline again occurring between middle (12 month) and older age (24 months).
Braidy et al. Sirtuins in the aging rat brain

Changes in Fatty Acid Oxidation

Nasrin et al. (2010) showed that SIRT4 regulates fatty acid oxidation and mitochondrial gene expression. To determine
FIGURE 2 | Reduced SIRT1 activity promotes p53 acetylation in the aging brain. Acetylated p53 and total p53 levels were determined by Western blotting in (A) frontal lobe, (B) temporal lobe, (C) occipital lobe, and (D) hippocampus in the brain with aging using anti-acetylated p53 and anti-total p53 antibodies. The blots shown are representative tracings of an experiment repeated eight times. Graphs are mean ± S.E brains of data from brains using eight rats for each age group. Significance *p < 0.01 was established by comparison with 3 month old rats.
whether altered SIRT4 expression can affect metabolic function in the aging rat brain, we measured fatty acid oxidation as a target of SIRT4 activity in various brain regions. Fatty acid oxidation significantly increased with age in the hippocampus and frontal lobe (Figure 5) consistent with a decrease in SIRT4 expression (Tables 1, 2, Supplementary Figure 6). The amount of fatty acid oxidation and SIRT4 expression did not change significantly in the temporal and occipital lobes.

Increased Acetylated CPS1 Correlates with Reduced SIRT5 Expression in the Hippocampus and Frontal Lobe
Nakagawa et al. (2009) recently showed that carbamoyl phosphate synthetase 1 (CPS1) is a SIRT5-binding protein. Consistent with this finding, we observed increased levels of acetylated CPS1 in the hippocampus and frontal lobe of the aging rat brain (Figure 6) in conjunction with decreased SIRT5 expression in these brain regions (Tables 1, 2, Supplementary Figure 7). Acetylated CPS1 levels in the temporal and occipital lobes remained unchanged, in line with observed pattern for SIRT5 expression.

SIRT6 May Regulate Histone Acetylation in the Aging Rat Brain
To explore a potential functional effect of increased SIRT6 expression in the aging brain, we measured H3K9 histone acetylation. We observed a significant increase in H3K9 acetylation in various brain regions (Figure 7) consistent with an age-dependent decline in SIRT6 expression (Tables 1, 2, Supplementary Figure 8), parallel to an increase in SIRT1 expression (Tables 1, 2, Supplementary Figure 2).

SIRT7 Can Influence Protein Transcription via Regulation of RNA Polymerase-I
Since SIRT7 can interact with Pol I (Ford et al., 2006), we tested the age-related effect of SIRT7 on Pol I expression. Our data shows that Pol I expression increases with age only in the frontal lobe (Figure 8), consistent with the observed increase in SIRT7 expression (Tables 1, 2, Supplementary Figure 9).

Discussion
Sirtuins are key NAD-dependent class III histone deacetylase enzymes that have been extensively investigated to determine
FIGURE 4 | Reduced MnSOD correlates with SIRT3 pattern of expression in the aging rat brain. Western blotting for MnSOD in (A) frontal lobe, (B) temporal lobe, (C) occipital lobe, and (D) hippocampus in the brain with aging using anti-MnSOD antibody. The blots shown are representative tracings of an experiment done eight times. Graphs are mean ± S.E brains from brains from eight different rats for each age group. Each bar of the quantification graph represents the corresponding band for each age group. Significance *p < 0.01 compared to 3 month old rats. (E) MnSOD activity in aged rat brain tissue. Significance *p < 0.01 compared to 3 month old rats. (F) Superoxide levels in aged rat brain tissue. Significance *p < 0.01 compared to 3 month old rats.
their role in various disease conditions (Chen et al., 2005; Denu, 2005, 2007; Anastasiou and Krek, 2006; Anekonnda and Reddy, 2006; Belenky et al., 2007; Chen and Guarente, 2007; Dali-Youcef et al., 2007). Numerous studies have highlighted the myriad of intrinsic and extrinsic biological effects, which play important neuroprotective roles in neurodegenerative and cerebrovascular conditions, including stroke, ischaemic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (Longo and Kennedy, 2006; Gan, 2007; Okawara et al., 2007; Milne and Denu, 2008; Pallas et al., 2008). However, to date, very little has been reported regarding mammalian sirtuin distribution and functional role in the central nervous system and to our knowledge this is the first study examining sirtuin expression and functional changes with aging.

SIRT1, the human ortholog of Sir2α, is localized predominantly in the nucleus of neurons, and regulates several important physiological processes such as chromatin remodeling, gene transcription, and the activity of several apoptotic mediators, particularly p53 (Pillai et al., 2005; Sauvé et al., 2006). Indeed, increased SIRT1 activity by mediators of caloric restriction, such as resveratrol have been shown to prolong lifespan by a number of different processes, including reduced apoptosis and improved DNA repair (Arraki et al., 2004; Borra et al., 2005; Raval et al., 2006; Qin et al., 2006). SIRT1 expression has been previously shown to progressively increase with age in both young and older endothelial cells. Although a significant increase in SIRT1 expression was reported

![FIGURE 5](image1.png)

**FIGURE 5 | SIRT4 protein expression regulates fatty oxidation in the aging rat brain.** Fatty acid oxidation in aged rat brain tissue. Significance *p < 0.01 compared to 3 month old rats.

![FIGURE 6](image2.png)

**FIGURE 6 | Raised acetylated CPS1 protein levels in the aging rat brain.** Western blotting for acetylated CPS1 in (A) frontal lobe, (B) temporal lobe, (C) occipital lobe, and (D) hippocampus in the brain with aging. The blots shown are representative tracings of an experiment done eight times.

Graphs are mean ± S.E brains from brains from eight different rats for each age group. Each bar of the quantification graph represents the corresponding band for each age group. Significance *p < 0.01 compared to 3 month old rats.
in young cell, a significant decline in SIRT1 was observed in older cells (Conti et al., 2015). This suggests that the SIRT1 pathway is more effective in younger cells. Oxidative stress may lead to a reduction in SIRT1 and its regulatory control on target proteins, thus promoting cellular senescence. Moreover, SIRT1 has been proposed to play a major role in neuroprotection. While several studies have demonstrated the protective roles of sirtuin activators during aging, little is known regarding the distribution or activity of SIRT1 in the aging brain. We have shown that aging is associated with increases in SIRT1 expression level, but decreases in the activity of SIRT1 in nuclear extracts from selected brain regions. The decreased activity of SIRT1 in the aging rat brain is consistent with the observed decrease in substrate (NAD\(^+\)) level that is observed during aging (Braidy et al., 2011). Oxidative damage may also potentially inhibit SIRT1 activity, as it does to several other proteins (Radak et al., 2009). The current observations are consistent with a previous study which reported decreased SIRT1 activity but not expression in skeletal muscle of aged rats (Koltai et al., 2010). It is also likely that the age-associated drop in NAD\(^+\) content due to increased demand by the DNA repair process may induce a compensatory increase in SIRT1 production to enhance its competitive advantage for the available NAD\(^+\) (Koltai et al., 2010). Exercise training has been shown to slow down the aging process by increasing SIRT1 activity, modulating an antioxidant response and mediating cell cycle regulation in aged rats (Ferrara et al., 2008).

FIGURE 7 | Raised acetylated H3K9 protein levels in the aging rat brain. Western blotting for acetylated H3K9 in (A) frontal lobe, (B) temporal lobe, (C) occipital lobe, and (D) hippocampus in the brain with aging. The blots shown are representative tracings of an experiment done eight times. Graphs are mean ± S.E brains from brains from eight different rats for each age group. Each bar of the quantification graph represents the corresponding band for each age group. Significance *p < 0.01 compared to 3 month old rats.

On the contrary to previous studies, Gong et al. (2014) recently showed that SIRT1 expression is reduced with age at the transcriptional and translational levels in the brain, liver, skeletal muscle, and white adipose tissue in senescence-accelerated mouse prone (SAM-P8) and a control counterpart strain, senescence-accelerated mouse resistant 1 (SAM-R1). Moreover SIRT1 expression levels were significantly lower in SAM-P8 compared to SAM-R1 mice (Gong et al., 2014). We postulate that SAM series may exhibit differential genetic backgrounds apart from the accelerated senescence-related ones which may alter both the expression and function of sirtuins (Ito, 2013).

The neuroprotective effects of SIRT1 are thought to be mediated in part by the deacetylation and hence inhibition of p53. We therefore measured the expression of both total and acetylated p53 in aging brain tissue. Our results show a significant
increase in acetylated p53 protein while no change was observed in total p53 protein content. This is consistent with work done by others showing that cells derived from SIRT1-deficient mice had elevated levels of acetylated p53 (Ford et al., 2005), and that sirtuin inhibition leads to hyperacetylated p53 (Yamakuchi et al., 2008). These results suggest that age-related changes in SIRT1 activity can regulate the post-translational acetylation of p53 (Pillai et al., 2005). Increased SIRT1 activity has been previously shown to repress p53 activity to prevent p53-dependent cellular senescence. It is therefore likely that our observation of concurrently decreased SIRT1 activity and increased p53 expression level are causally linked. Our present study provides supporting evidence for an age related change in the brain SIRT1-p53 axis that is consistent across at least four cortical regions. These age related changes to SIRT1 activity, and in turn p53 expression, may be driven by availability and changes in brain levels of NAD⁺, which are known to decrease during aging (Braidy et al., 2011). Ramadori et al. (2008) recently showed that reduced energy availability can lead to lower levels of acetylated p53 only in the hypothalamus and hindbrain within the normal brain, and the effect is altered in leptin-deficient obese mice (Ramadori et al., 2008). Level of NAD⁺ may therefore be central to regulation of a variety downstream effects on senescence regulating proteins; however, further work is needed to investigate these relationships.

SIRT2 has been shown to promote longevity in yeast, nematodes and fruitflies, although the life-span promoting effect has not been observed in humans (Lamming et al., 2004). In human cells, SIRT2 has been shown to mediate cell survival through mitotic control (Dryden et al., 2003). SIRT2 regulates microtubule dynamics by deacetylating several cytoskeletal proteins including tubulin, and regulates cell cycle progression (North et al., 2003). Overexpression of SIRT2 has been reported to lengthen mitosis, and reduced expression of SIRT2 has an
Sirtuins in the aging rat brain

antiapoptotic effect (Dryden et al., 2003; North et al., 2003). Compared to the other sirtuins, SIRT2 expression has been found to be greatest in the brain (Pandithage et al., 2008). Although SIRT2 is mainly found in oligodendrocytes, and myelin-forming glial cells (Pandithage et al., 2008), SIRT2 has been recently described in the cytoplasm of hippocampal neurons in the adult mouse brain (Li et al., 2007). There is argument for (Werner et al., 2007) and against the localization of SIRT2 in astrocytes (Li et al., 2007), the second major brain glial cell type. However, other studies have shown that SIRT2 is present in both neurons and astrocytes (Michan and Sinclair, 2007; Werner et al., 2007; Pandithage et al., 2008; Ramadori et al., 2008).

To investigate the effect of SIRT2 function during aging, we examined the levels of FOXO3 protein levels in the aging brain. Our study shows that both SIRT2 and FOXO3 undergo age related expression changes only in the occipital lobe, and that in this case their expression levels are inversely related. The FOXO transcription factors are regulated by post-translational modifications, and SIRT2-mediated deacetylation of FOXO3 can influence FOXO3 ubiquitination and degradation (Wang et al., 2011). Brunet et al. (2004) showed that SIRT2 deacetylation of FOXO protein can activate a myriad of genes that may regulate cell survival, thus shifting vulnerable cells from apoptosis toward growth arrest and DNA repair (Brunet et al., 2004). However, the significance of the upregulated SIRT2 in the occipital lobe with aging cannot be easily interpreted in the light of brain aging. The biological significance of its upregulation in the occipital lobe with aging, in all of its cellular locales, is not immediately apparent, but its cellular distribution supports currently known roles.

We and others have previously shown that increased ROS formation and reduced mitochondrial efficiency may contribute to impaired physiological function, increased incidence of disease, and a reduction in life span (Beal, 1995, 2003, 2007; Budd and Nicholls, 1996; La Piana et al., 1998; Budd et al., 2000; Gibson et al., 2000; Menzies et al., 2002a,b; Jacquard et al., 2006; Ahn et al., 2008; Brady et al., 2011). Therefore, it is highly likely that acetylation of mitochondrial proteins may play a critical role in regulating mitochondrial ROS levels (Ozden et al., 2011). SIRT3 is the main mitochondrial deacetylase (Shi et al., 2005; Ahn et al., 2008), and SIRT3 knockout studies have shown an increase in ROS, including the levels of the highly reactive superoxide anion both in vitro and in vivo (Lombard et al., 2007). Therefore, SIRT3 appears to represent a regulatory molecule that maintains mitochondrial homeostasis by mediating the acetylation of metabolic target protein, including those that form part of the endogenous antioxidant defense system. This is the first study to show that brain SIRT3 expression levels decline with age and in parallel with lower MnSOD protein levels, MNSSOD activity, and increased superoxide (O$_2^−$) levels in the rat hippocampus and frontal lobe. This is relevant to Alzheimer’s disease where the hallmarks of the disease (i.e., senile plaques and neurofibrillary tangles) are predominantly observed in the hippocampus and frontal lobe of the brain (Alafuzoff et al., 1987).

MnSOD is the primary mitochondrial antioxidant enzyme which neutralizes O$_2^−$ to the less reactive hydrogen peroxide (H$_2$O$_2$) followed by conversion to H$_2$O by catalase in the mitochondrial matrix (Oberley and Oberley, 1988). Superoxide is a byproduct of normal oxidative phosphorylation and ATP production and can lead to extensive damage to lipids, proteins and DNA (Henderson et al., 2009). Since MnSOD enzymatically scavenges superoxide, whose levels are significantly increased in SIRT3-deficient cells (Spitz and Oberley, 1989), it seems likely that an age-related reduction in SIRT3 expression may lead to reduced MnSOD activity and thereby higher oxidative damage and altered redox signaling. Tao et al. (2010) recently showed that SIRT3-mediated deacetylation of Lysine 122 can regulate MnSOD activity in response to stress (Tao et al., 2010). While the current data does not indicate a definite relationship between SIRT3-mediated acetylation of MnSOD during pathological processes, it is highly likely that SIRT3 may play a protective role against ROS by regulating the enzymatic properties of MnSOD during aging and particularly in chronic age-induced oxidative stress.

SIRT4 is another mitochondrial sirtuin that may be altered in the brain during the aging process. Recently, SIRT4 has been shown to inactivate glutamate dehydrogenase, an enzyme which converts glutamate to α-ketoglutarate in the mitochondria in an NAD$^+$ dependent manner (Haigis et al., 2006). Although the function of SIRT4 remains unclear, we speculated that SIRT4 might be involved in mitochondrial oxidative metabolism. Nasrin et al. (2010) recently showed that SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. SIRT4 knockdown in hepatocytes also increased SIRT1 mRNA protein levels both in vitro and in vivo, suggesting that the effect of SIRT4 on fatty acid oxidation may be SIRT1 dependent (Nasrin et al., 2010). Here, we show a significant increase in fatty acid oxidation in the aging rat brain in the hippocampus and frontal lobe which is closely associated with a reduction in SIRT4 expression. How SIRT4 regulates fatty acid oxidation with aging is unknown, but could be related to changes in NAD$^+$/NADH and/or AMP/ATP ratios. Another possibility is the role of SIRT4 in modulating AMPK-SIRT1 pathways (Nasrin et al., 2010). Activation of AMPK increases NAD$^+$ levels which can increase SIRT1-mediated deacetylation of Lxβ1 which increases acetyl-CoA carboxylase (ACC) phosphorylation, leading to increased fatty acid oxidation (Nasrin et al., 2010). Alternatively, it is possible that SIRT1 increases as a compensatory effect to replace SIRT4 function in SIRT4-knockout mice (Nasrin et al., 2010). Therefore, sirtuins may represent a synergistic network which regulates metabolic signals and mitochondrial function during aging.

While SIRT3 and SIRT4 appear to directly modulate the activity of mitochondrial enzymes associated with energy metabolism, little is known regarding the cellular role of SIRT5. Our data is the first to show an age related reduction in SIRT5 expression in the hippocampus and frontal lobe, consistent with the expression changes of the other two mitochondrial sirtuins, SIRT3 and SIRT4. Our data support the findings by Nakagawa et al. (2009) who showed that SIRT5 could deacetylate CPS1 in a NAD-dependent manner and this deacetylation increased CPS1 enzymatic activity (Nakagawa et al., 2009). Indeed, SIRT5 knockout mice have ~30% reduction in CPS1 activity compared to wild type mice. During fasting conditions, calorie restriction
or following consumption of a high protein diet, SIRT5 deficient mice failed to up-regulate CPS1 activity resulting in hyperammonemia (Nakagawa et al., 2009). Taken together, these data indicate that SIRT5 has an emerging role in the metabolic changes that take place during aging.

Like SIRT1, SIRT6 is another chromatin-associated nuclear protein that has been shown to affect DNA repair, telomere maintenance, gene expression, and metabolism (Mostoslavsky et al., 2006). We have shown that SIRT6 expression declines with age in the frontal, temporal, occipital lobes and hippocampus in the aging rat brain. SIRT6 deficient mice have a significantly reduced lifespan and suffer from severe multisystemic phenotypes (Mostoslavsky et al., 2006). SIRT6 can deacetylate histone H3K9, a chromatin marker that is associated with longevity (Schwer et al., 2010). Histone acetylation is relevant to several neurodegenerative diseases including schizophrenia, depression, addiction, and various neurodevelopment disorders (Schwer et al., 2010). However, the mechanism by which SIRT6 can regulate histone acetylation in the brain during aging remains obscure. We analyzed H3K9 acetylation in several brain regions. Our data indicates a significant increase in H3K9 acetylation in various brain regions consistent with an age-dependent decline in SIRT6 expression, and occurs parallel to an increase in SIRT1 expression. Loss of SIRT6 has been shown to induce dramatic H3K9 hyperacetylation in the hypothalamus, cortex, hippocampus and cerebellum, and in purified brain nuclei. Similarly, increased acetylation of H3K9 has been reported in SIRT6 deficient mice, while the acetylation levels of other histones remained unaffected (Schwer et al., 2010). Together, these results suggest that SIRT6 is the main H3K9 deacetylase in the brain, suggesting a potential role in gene regulation with age.

We also investigated the role of SIRT7 in the aging rat brain. Our data shows that SIRT7 is upregulated in the frontal lobe with aging. Ford et al. (2006) showed that SIRT7 can interact with Polymerase-I (Pol I) (Ford et al., 2006). As transcription of rDNA by Pol I accounts for 65% of total transcription in mammalian cells, Pol I appears to be highly coordinated with cellular metabolism and cellular proliferation (Grummt, 2003). We found that Pol I expression increases with age only in the frontal lobe, consist with the observed increase in SIRT7 expression. In yeast, Sinclair and Guarente (1997) showed that Sir2 can mediate longevity, primarily through its silencing role at the rDNA (Sinclair and Guarente, 1997). Therefore, maintenance of cellular energy status may be coupled with levels of RNA synthesis, protein transcription, and therefore cell growth, which is dysregulated during the aging process.

Sirtuins represent a unique class of enzymes that not only regulate protein acetylation and metabolism, but also play prominent roles in promoting longevity, preventing disease and improving cell survival. Our present study describes the anatomical landscape of mammalian sirtuins and their downstream targets within the brain (Supplementary Figure 10). On the contrary to our finding, a recent study showed that no significant decreases in the expression of any sirtuin member were observed in any brain region between the 24 month old and 3 month old Wistar rats. As well, the mRNA expression patterns for specific sirtuins were never parallel to its corresponding translational expression pattern in that study (Sidorova-Darmos et al., 2014). However, the cellular biology of altered sirtuin expression in various brain regions remains unknown. It is unclear which cells in the brain contain sirtuins. Previous studies have suggested that only specific neuronal brain cells may express functional sirtuin protein (Hasahara et al., 2005; Sidorova-Darmos et al., 2014). Sidorova-Darmos et al. (2014) further examined the expression patterns of sirtuins in murine brain cells. While SIRT2 mRNA was largely expressed in both neurons and astrocytes, SIRT2 protein was expressed in astrocytes only. Similarly, SIRT5 was expressed at the translational level in neurons, although its mRNA was also identified in both astrocytes and neurons (Sidorova-Darmos et al., 2014). If this hypothesis is correct, then only certain cells may be responsible for the age-related effects in the brain. Additionally, the effects of calorie restriction on sirtuin activity in specific brain regions and certain brain cells have not been investigated. The fact that all mitochondrial sirtuins are expressed in brain neurons is important with respect to their protective roles against neurodegeneration. Taken together, our results provide additional evidence for the role of sirtuins in regulating brain function at different stages of development. It also identifies the potential for pharmacologically targeting specific sirtuins to establish cell-specific effects within the brain.

Author Contributions

Conceived and designed the experiments: NB, AP, PS, GS, TJ. Performed the experiments: NB, TJ, HM. Analyzed the data: NB, AP, PS. Contributed reagents/materials/analysis tools: GG, TC, PS. Wrote the paper: NB, AP, PS. All authors reviewed the manuscript.

Acknowledgments

This work was supported by a Capacity Building Grant from the National Health and Medical Research Council of Australia, and a UNSW Faculty of Medicine Research Grant. NB is the recipient of an Alzheimer’s Australia Viertel Foundation Postdoctoral Research Fellowship at the University of New South Wales. TJ is a recipient of the University of New South Wales Postgraduate Award (UPA).

Supplementary Material

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fncel.2015.00167/abstract
References

Ahn, B., Kim, H., Song, S., Lee, I., Liu, J., Vassilopoulos, A., et al. (2008). A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105, 14447–14452. doi: 10.1073/pnas.0803790105

Alafuzoff, I., Iqbal, K., Frieden, H., Adolfsen, R., and Winblad, B. (1987). Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. (Berl) 74, 209–225. doi: 10.1007/BF00688184

Anastasiou, D., and Krek, W. (2006). SIRT1: linking adaptive cellular responses to aging-associated changes in organismal physiology. Physiology (Bethesda) 21, 404–410. doi: 10.1152/physiol00031.2006

Andersen, J. (2004). Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10(Suppl.), S18–S25. doi: 10.1038/nrn1434

Anekonda, T. S., and Reddy, P. H. (2006). Neuronal protection by sirtuins, forkheads and 14-3-3 proteins. Cell Cycle 5, 2588–2591. doi: 10.1186/cc4770.x

Arraki, T., Sasaki, A., and Milbrandt, J. (2004). Stress-dependent regulation of SIRT1 activation by resveratrol. J. Biol. Chem. 280, 40364–40374. doi: 10.1074/jbc.M501250200

Braidy, N., Guillemin, G. M. H., Chan-Ling, T., Poljak, A., and Grant, R. (2011). Oxidative stress in serum and peripheral blood leukocytes of patients with different disease courses of multiple sclerosis. J. Pharcop. Sci. 105, 14447–14452. doi: 10.1073/pnas.100122-Z

Beal, M. F. (2005). Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann. N.Y. Acad. Sci. 991, 120–131. doi: 10.1111/j.1749-6632.2003.tb07470.x

Beal, M. F. (2007). Mitochondria and neurodegeneration. Trends Mol. Med. 13, 1–16. doi: 10.1016/j.trendsmm.2006.06.057

Beal, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Alzheimer’s disease. Ann. Neurol 54, 28–38. doi: 10.1002/ana.10539

Beal, M. F. (1995). Aging, energy, and oxidative stress in neurodegenerative disease. Ann. Rev. Physiol. 57, 219–255. doi: 10.1146/annurev.physiol.57.1.219

Birch-Machin, M. (2009). Direct, real-time monitoring of superoxide production by isolated mitochondria. Proc. Natl. Acad. Sci. U.S.A. 106, 21396–21401. doi: 10.1073/pnas.0904147106

Birkenmeier, E. H., Eberwine, J. H., and Sussman, A. (2005). Sirtuin expression in human glioblastoma and glioma cell lines. Cancer. Lett. 221, 113–120. doi: 10.1016/j.canlet.2005.05.035

Blake, J. L., Stoger, R., Hogervorst, A., Hwang, L. S., Schuurman, H. J., Breitbeck, S., et al. (2004). NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 231–235. doi: 10.1126/science.1098503

Bock, D. S., Tew, K. D., and Lott, V. G. (2006). Induction of SIRT1 expression by resveratrol. J. Biol. Chem. 281, 30905–30910. doi: 10.1074/jbc.M509003200

Bollinger, J. L., Weng, L., Sies, J., and Seeley, W. (2005). Sirtuins mediate Cd2+ uptake and cadmium toxicity in mammalian cells. Drug Metab. Dispos. 33, 1304–1309. doi: 10.1124/dmd.31.11.1337

Braun, A. D., and Kovarik, L. (2006). Sirtuin family members in the aging rat brain. Frontiers in Cellular Neuroscience | www.frontiersin.org 11

Braidy, N., Guillemin, G. M. H., Chan-Ling, T., Poljak, A., and Grant, R. (2011). Oxidative stress in serum and peripheral blood leukocytes of patients with different disease courses of multiple sclerosis. J. Neurochem. 121, 21–28. doi: 10.1016/j.jconcd.2009.11.002

Braithwaite, A. B., and Wood, C. H. (2006). The sirtuin family of NAD+-dependent deacetylases. J. Biol. Chem. 281, 10457–10463. doi: 10.1074/jbc.M503916200

Braun, A. D., and Kovarik, L. (2006). Sirtuin family members in the aging rat brain. Frontiers in Cellular Neuroscience | www.frontiersin.org 11

Braidy, N., Guillemin, G. M. H., Chan-Ling, T., Poljak, A., and Grant, R. (2011). Oxidative stress in serum and peripheral blood leukocytes of patients with different disease courses of multiple sclerosis. J. Neurochem. 121, 21–28. doi: 10.1016/j.jconcd.2009.11.002

Braithwaite, A. B., and Wood, C. H. (2006). The sirtuin family of NAD+-dependent deacetylases. J. Biol. Chem. 281, 10457–10463. doi: 10.1074/jbc.M503916200
Palladino, R., Lishchikis, R., Harting, K., Wolf, A., Jedamzik, B., Lusher-Firzlaff, J., et al. (2008). The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J. Cell Biol. 180, 915–929. doi: 10.1083/jcb.200707126
Pilla, J. B., Ishbata, A., Imai, S. L., and Gupta, M. P. (2005). Poly(ADP-ribose) polymerase-I dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sirt2 deacetylation activity. J. Biol. Chem. 280, 43121–43130. doi: 10.1074/jbc.M506162200
Porcu, M., and Chiarugi, A. (2005). The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci. 26, 94–103. doi: 10.1016/j.tips.2004.12.009
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., et al. (2006). Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 21745–21754. doi: 10.1074/jbc.M602909200
Radak, Z., Atalay, M., Jakus, J., Boldog, I., Davies, K., and Goto, S. (2009). Exercise improves import of 8-oxoguanine DNA glycosylase into the mitochondrial matrix of skeletal muscle and enhances the relative activity. Free Radic. Biol. Med. 46, 153–159. doi: 10.1016/j.freeradbiomed.2008.10.022
Ramadori, G., Lee, C., Bookout, A., Lee, S., Williams, K., Anderson, J., et al. (2008). Brain SIRT1: anatomical distribution and regulation by energy availability. J. Neurosci. 28, 9998–9999. doi: 10.1523/JNEUROSCI.3257-08.2008
Raval, A. P., Dave, K. R., and Perez-Pinzon, M. A. (2006). Resveratrol mimics ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab. 26, 1141–1147. doi: 10.1093/jcbfm/600262
Saavedra, A. A., Wolberger, C., Schraerm, V. L., and Boeke, J. D. (2006). The biochemistry of sirtuins. Annu. Rev. Biochem. 75, 435–465. doi: 10.1146/annurev.biochem.74.028803.133500
Schwer, B., Schumacher, B., Lombard, D., Cuiying, X., Kurtev, M., Gao, J., et al. (2010). Neuronal sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc. Natl. Acad. Sci. U.S.A. 107, 21790–21794. doi: 10.1073/pnas.1016306107
Schwer, B., and Verdin, E. (2008). Conserved metabolic regulatory functions of sirtuins. Cell Metab. 7, 104–112. doi: 10.1016/j.cmet.2007.11.006
Shi, T., Wang, F., Stieren, E., and Tong, Q. (2005). SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 280, 13560–13567. doi: 10.1074/jbc.M414670200
Sidorova-Darmos, E., Wither, R. G., Shulyakova, N., Fisher, C., Ratnam, M., Aarts, M., et al. (2014). Differential expression of sirtuin family members in the developing, adult, and aged rat brain. Front. Aging Neurosci. 6, 333. doi: 10.3389/fnagi.2014.00333
Smith, J. (2002). Human Sir2 and the ‘silencing’ of p53 activity. Trends Cell Biol. 12, 404–406. doi: 10.1016/S0962-8924(02)02342-5
Spitz, D., and Oberley, L. (1989). An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal. Biochem. 179, 8–18. doi: 10.1016/0003-2697(89)90192-9
Tang, B. L., and Chua, C. E. (2008). SIRT1 and neuronal diseases. Mol. Aspects Med. 29, 187–200. doi: 10.1016/j.mam.2007.02.001
Tao, R., Coleman, M., Pennington, J., Ozden, O., Park, S., Jiang, H., et al. (2010). Sirt3-mediated deacetylation of evolutionary conserved Lysine 122 regulates MnSOD activity in response to stress. Mol. Cell 40, 893–904. doi: 10.1016/j.molcel.2010.12.013
van der Horst, A., Tertoolen, L. G., de Vries-Smits, L. M., Fye, R. A., Mederna, R. H., and Burgering, B. M. (2004). FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein Sirt1 (SIRT1). J. Biol. Chem. 279, 28873–28879. doi: 10.1074/jbc.M401138200
Wang, F., Chan, C. H., Chen, K., Guan, X., Lin, H.-K., and Tong, Q. (2011). Deacetylation of FOXO3 by SIRT1 and SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 31, 1546–1557. doi: 10.1038/onc.2011.347
Wheeler, H., Kuhlmann, K., Shen, S., Uecker, M., Schardt, A., Dimova, K., et al. (2007). Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J. Neurosci. 27, 7717–7730. doi: 10.1523/JNEUROSCI.1245-07.2007
Yamakuchi, M., Ferlito, M., and Lowenstein, C. (2008). miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13421–13426. doi: 10.1073/pnas.080163105

References
Yang, T., and Sauve, A. A. (2005). NAD+ metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J. 8, E632–E643. doi: 10.1208/aapsj080472

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.